Jiangsu Jibeier Pharmaceutical Co., Ltd. (SHA:688566)

SHA:688566 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	602.24	781.43	847.52	694.87	903.9	1,025
Short-Term Investments	-	31.04	-	-	-	-
Trading Asset Securities	267.03	37.03	56	35	90	200
Cash & Short-Term Investments	869.27	849.51	903.52	729.87	993.9	1,225
Cash Growth	-8.54%	-5.98%	23.79%	-26.57%	-18.87%	-4.84%
Accounts Receivable	325.02	366.28	365.92	369.15	216.21	146.6
Other Receivables	0.6	1.12	0.05	0.03	0.02	-
Receivables	325.62	367.4	365.97	369.17	216.23	146.6
Inventory	36.37	34.07	30.7	29.51	32.66	31.83
Other Current Assets	18.86	3.59	4.25	2.59	13.98	2.62
Total Current Assets	1,250	1,255	1,304	1,131	1,257	1,406
Property, Plant & Equipment	1,058	1,031	986.86	832.49	552.21	271.51
Long-Term Investments	82.87	231.89	110.16	126.19	61.74	56.63
Goodwill	35.33	35.33	-	-	-	-
Other Intangible Assets	57.06	58.03	56.69	58.2	59.74	61.28
Long-Term Deferred Tax Assets	23.05	22.64	17.93	16.13	15.59	11.72
Long-Term Deferred Charges	65.27	59.74	32.14	1.13	2.18	3.25
Other Long-Term Assets	210.67	24.23	19.33	44.38	16.34	8.21
Total Assets	2,782	2,717	2,528	2,210	1,965	1,819

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	72.6	74.29	97.15	91.22	101.67	69.92
Accrued Expenses	16.14	51.32	45.73	86.79	53.49	35.3
Short-Term Debt	12.32	16.52	20.83	9.91	-	-
Current Income Taxes Payable	28.08	7.71	2.01	0.19	6.09	5.19
Current Unearned Revenue	5.96	6.4	0.95	1.81	3.42	1.51
Other Current Liabilities	24.03	20.78	18.53	20.39	16.69	12.14
Total Current Liabilities	159.12	177.01	185.19	210.31	181.36	124.06
Long-Term Debt	-	2.2	-	-	-	-
Long-Term Unearned Revenue	61.12	58.39	58.59	59.04	58.85	59.7
Long-Term Deferred Tax Liabilities	2.93	3.23	3.25	3.25	3.4	-
Other Long-Term Liabilities	26.64	26.64	26.64	26.64	26.64	26.64
Total Liabilities	249.82	267.47	273.68	299.25	270.24	210.4

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	201.1	199.43	199.43	189.08	186.94	186.94
Additional Paid-In Capital	1,360	1,323	1,299	1,082	1,042	1,021
Retained Earnings	954.63	907.68	749.77	633.4	459.17	394.24
Comprehensive Income & Other	0.1	0.01	-	-	-	-
Total Common Equity	2,515	2,430	2,249	1,905	1,688	1,602
Minority Interest	17.12	19.6	5.23	5.58	5.9	6.31
Shareholders' Equity	2,533	2,450	2,254	1,910	1,694	1,608
Total Liabilities & Equity	2,782	2,717	2,528	2,210	1,965	1,819

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	12.32	18.72	20.83	9.91	-	-
Net Cash (Debt)	856.95	830.79	882.69	719.96	993.9	1,225
Net Cash Growth	-6.57%	-5.88%	22.60%	-27.56%	-18.87%	-4.84%
Net Cash Per Share	4.30	4.16	4.55	3.84	5.33	6.50
Filing Date Shares Outstanding	196.98	199.43	199.43	189.08	186.94	186.94
Total Common Shares Outstanding	196.98	199.43	199.43	189.08	186.94	186.94
Working Capital	1,091	1,078	1,119	920.84	1,075	1,282
Book Value Per Share	12.77	12.18	11.28	10.07	9.03	8.57
Tangible Book Value	2,423	2,337	2,192	1,847	1,629	1,541
Tangible Book Value Per Share	12.30	11.72	10.99	9.77	8.71	8.24
Buildings	-	312.04	142.66	142.66	142.52	142.52
Machinery	-	99.21	75.26	74.81	73.37	72.78
Construction In Progress	-	784.03	917.62	754.62	466.36	175.48

Data Source: S&P Global Market Intelligence Last updated: Aug 27, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 10, 2026

Data Sources Report a data error